Prognostic Value of Inflammatory and Nutritional Biomarkers of Immune Checkpoint Inhibitor Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Authors:
- Akihiro SakaiASAkihiro Sakai
- Hiroaki IijimaHIHiroaki Iijima
- Koji EbisumotoKEKoji Ebisumoto
- Mayu YamauchiMYMayu Yamauchi
- Takanobu TeramuraTTTakanobu Teramura
- Aritomo YamazakiAYAritomo Yamazaki
- Takane WatanabeTWTakane Watanabe
- Toshihide InagiTIToshihide Inagi
- Daisuke MakiDMDaisuke Maki
- Kenji OkamiKOKenji Okami
Open Access
Abstract
This study aimed to determine the prognostic value of inflammatory and nutritional biomarkers of immune checkpoint inhibitor (ICI) therapy for recurrent or metastatic squamous cell carcinoma of the head and neck (RMHNSCC) and to identify the most useful factor for prognosis assessment. We retrospectively reviewed the medical records of patients with RMHNSCC who received ICI therapy. The response rate for ICI therapy and the relationship between inflammatory and nutritional biomarkers and overall survival were examined. The included biomarkers did not correlate with an objective response rate but were associated with a disease control rate. Univariate analysis showed significant correlations between the serum albumin level, C-reactive protein level, platelet to lymphocyte ratio, neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio (LMR), systemic immune-inflammation index, and controlling the nutritional status score and overall survival; multivariate analysis showed that LMR was significantly correlated with overall survival. LMR was the most important biomarker according to the machine learning model. This study suggests that LMR may be the most useful biomarker for predicting the prognosis of ICI treatment for RMHNSCC.Keywords
Funding Information
- Institutional Research Facilitation Fund (22F-144100)
This publication has 50 references indexed in Scilit:
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialThe Lancet Oncology, 2016
- Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancerOral Oncology, 2016
- PD-L1 Expression as a Predictive Biomarker in Cancer ImmunotherapyMolecular Cancer Therapeutics, 2015
- Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular CarcinomaClinical Cancer Research, 2014
- The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patientsMedical Oncology, 2014
- Global epidemiology of oral and oropharyngeal cancerOral Oncology, 2009
- Random survival forestsThe Annals of Applied Statistics, 2008
- Cancer-related inflammationNature, 2008
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001